These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35093913)

  • 1. Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
    Anticancer Res; 2022 Feb; 42(2):1107-1114. PubMed ID: 35093913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
    Rossignol T; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
    Prostate; 2021 Oct; 81(14):1091-1096. PubMed ID: 34320690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
    Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
    Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer.
    Qin XJ; Ma CG; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Xiao WJ; Lin GW; Swanson GP
    Urol Oncol; 2012; 30(2):145-9. PubMed ID: 20451424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
    Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy.
    Wong KW; Ma WK; Wong CW; Wong MH; Tsang CF; Tsu HL; Ho KL; Yiu MK
    Hong Kong Med J; 2016 Apr; 22(2):106-15. PubMed ID: 26635306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
    Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
    Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
    Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S
    BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
    Weiner AB; Nettey OS; Morgans AK
    Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
    Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
    Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent versus continuous androgen deprivation in prostate cancer.
    Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
    N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study.
    Kawahara T; Yoneyama S; Ohno Y; Iizuka J; Hashimoto Y; Tsumura H; Tabata KI; Nakagami Y; Tanabe K; Iwamura M; Uemura H; Miyoshi Y
    Biomed Res Int; 2020; 2020():7804932. PubMed ID: 32714984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
    Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
    BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
    Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.